The mechanisms behind the possibility of using α-Gal for developing a single-antigen pan-vaccine for the control of infectious diseases caused by pathogens with this modification on their surface include pathogen opsonization by anti-α-Gal IgM/IgG-type antibodies and boosting the non-pathogen-specific protective immune mechanisms [10,14,15,16,17,18,19,20,21]. This evidence concerns the gene CD40LG and infectious disease.